AbbVie Inc (ABBV)vsThe Cooper Companies, Inc (COO)
ABBV
AbbVie Inc
$291.27
+1.05%
HEALTHCARE · Cap: $521.11B
COO
The Cooper Companies, Inc
$63.51
-1.41%
HEALTHCARE · Cap: $11.30B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1458% more annual revenue ($66.01B vs $4.24B). ABBV leads profitability with a 15.7% profit margin vs 13.5%. COO appears more attractively valued with a PEG of 0.56. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
COO
Strong Buy71
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.0%
Fair Value
$156.84
Current Price
$291.27
$134.43 premium
Margin of Safety
+59.9%
Fair Value
$207.07
Current Price
$63.51
$143.56 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 357.1% YoY
Growing faster than its price suggests
Strong operational efficiency at 20.8%
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.6% revenue growth
ROE of 6.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : COO
The strongest argument for COO centers on Price/Book, EPS Growth, PEG Ratio. PEG of 0.56 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : COO
The primary concerns for COO are Revenue Growth, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a mature stock while COO is a value play — different risk/reward profiles.
COO carries more volatility with a beta of 0.82 — expect wider price swings.
ABBV is growing revenue faster at 10.3% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 71/100), backed by strong 15.7% margins and 10.3% revenue growth. COO offers better value entry with a 59.9% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
The Cooper Companies, Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?